Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baton Rouge, LA
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lafayette, LA
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lafayette, LA
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Southgate, MI
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Southgate, MI
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, MS
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, MS
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Gulfport, MS
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Gulfport, MS
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sewell, NJ
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sewell, NJ
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Great Neck, NY
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mineola, NY
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mineola, NY
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ridgewood, NY
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ridgewood, NY
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rosedale, NY
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rosedale, NY
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wilmington, NC
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Burlington, VT
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fairfax, VA
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Portsmouth, VA
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Portsmouth, VA
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Madison, WI
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated:  12/31/1969
mi
from
Feldkirch,
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status: Enrolling
Updated: 12/31/1969
mi
from
Feldkirch,
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Northern California
mi
from
Oakland, CA
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Northern California
mi
from
Oakland, CA
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University of California
mi
from
San Francisco, CA
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University of California
mi
from
San Francisco, CA
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University of Illinois at Chicago
mi
from
Chicago, IL
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Tulane University Health Sciences Center
mi
from
New Orleans, LA
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University of Maryland Medical System
mi
from
Baltimore, MD
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University of Maryland Medical System
mi
from
Baltimore, MD
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University of Michigan Hospitals
mi
from
Ann Arbor, MI
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University of Michigan Hospitals
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
St. John Hospital and Medical Center/RRRI
mi
from
Detroit, MI
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
St. John Hospital and Medical Center/RRRI
mi
from
Detroit, MI
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Wayne State - Harper University Hospital
mi
from
Detroit, MI
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Wayne State - Harper University Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
MetroHealth Med Ctr
mi
from
Cleveland, OH
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
University Hospitals of Cleveland
mi
from
Cleveland, OH
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated:  12/31/1969
The University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
Prospective Cohort Study of Chronic Renal Insufficiency
Status: Enrolling
Updated: 12/31/1969
The University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Glendale, AZ
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Azusa, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Azusa, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chula Vista, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Downey, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Downey, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
El Centro, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
El Centro, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Mesa, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Mesa, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Riverside, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Arvada, CO
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Arvada, CO
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Westminster, CO
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Westminster, CO
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lauderdale Lakes, FL
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lauderdale Lakes, FL
Click here to add this to my saved trials
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Port Charlotte, FL
20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Port Charlotte, FL
Click here to add this to my saved trials